Papers by Hagop M. Kantarjian
Page 6 · newest first
- Improved survival of patients with myelofibrosis in the last decade: Single‐center experienceCancer · 2022
- Impact of F LT3 Mutation on Outcomes after Venetoclax and Azacitidine for Patients with Treatment-Naïve Acute Myeloid LeukemiaClinical Cancer Research · 2022
- Characteristics and outcomes of patients with blastic plasmacytoid dendritic cell neoplasm treated with frontline HCVADBlood Advances · 2022
- Retrospective analysis of arterial occlusive events in the PACE trial by an independent adjudication committeeENLIGHTEN (Jurnal Bimbingan dan Konseling Islam) · 2022
- Improved outcomes among newly diagnosed patients with FMS‐like tyrosine kinase 3 internal tandem duplication mutated acute myeloid leukemia treated with contemporary therapy: Revisiting the European LeukemiaNet adverse risk classificationAmerican Journal of Hematology · 2022
- The Evolution of Research and Therapy With Hypomethylating Agents in Acute Myeloid Leukemia and Myelodysplastic Syndrome: New Directions for Old DrugsThe Cancer Journal · 2022
- Venetoclax for Children and Adolescents with Acute Lymphoblastic Leukemia and Lymphoblastic LymphomaCancers · 2021
- Blinatumomab maintenance after allogeneic hematopoietic cell transplantation for B-lineage acute lymphoblastic leukemiaBlood · 2021
- Impact of Blinatumomab Treatment on Bone Marrow Function in Patients with Relapsed/Refractory B-Cell Precursor Acute Lymphoblastic LeukemiaCancers · 2021
- Freeze‐dried platelets are a promising alternative in bleeding thrombocytopenic patients with hematological malignanciesAmerican Journal of Hematology · 2021
- Azacitidine, Venetoclax and Pevonedistat As Frontline Therapy for Patients with Secondary Acute Myeloid Leukemia Who Are Unfit for Intensive Chemotherapy: Results from a Phase I/II StudyBlood · 2021
- Final Results of a Phase 2 Study of Sotatercept (ACE-011) for Anemia of MPN-Associated MyelofibrosisBlood · 2021
- Safety and Efficacy of Cusatuzumab in Combination with Venetoclax and Azacitidine (CVA) in Patients with Previously Untreated Acute Myeloid Leukemia (AML) Who Are Not Eligible for Intensive Chemotherapy; An Open-Label, Multicenter, Phase 1b StudyBlood · 2021
- Long Term Follow-up and Combined Phase 2 Results of Eprenetapopt (APR-246) and Azacitidine (AZA) in Patients with TP53 mutant Myelodysplastic Syndromes (MDS) and Oligoblastic Acute Myeloid Leukemia (AML)Blood · 2021
- Prediction of early (4‐week) mortality in acute myeloid leukemia with intensive chemotherapyAmerican Journal of Hematology · 2021
- The cure of leukemia through the optimist's prismCancer · 2021
- TP53 in Acute Myeloid Leukemia: Molecular Aspects and Patterns of MutationInternational Journal of Molecular Sciences · 2021
- Predictors of outcomes in adults with acute myeloid leukemia and KMT2A rearrangementsSHILAP Revista de lepidopterología · 2021
- Outcomes of acute lymphoblastic leukemia with KMT2A (MLL) rearrangement: the MD Anderson experienceBlood Advances · 2021
- Ibrutinib induces durable remissions in treatment-naïve patients with CLL and 17p deletion and/or TP53 mutationsBlood · 2021
- Prognostic impact of conventional cytogenetics in acute myeloid leukemia treated with venetoclax and decitabineLeukemia & lymphoma/Leukemia and lymphoma · 2021
- Results of a randomized phase 3 study of oral sapacitabine in elderly patients with newly diagnosed acute myeloid leukemia (SEAMLESS)Cancer · 2021
- Clinical and molecular characterization of myeloid sarcoma without medullary leukemiaLeukemia & lymphoma/Leukemia and lymphoma · 2021
- Development of TP53 mutations over the course of therapy for acute myeloid leukemiaAmerican Journal of Hematology · 2021
- Ten‐day decitabine with venetoclax versus intensive chemotherapy in relapsed or refractory acute myeloid leukemia: A propensity score‐matched analysisCancer · 2021
- Phase II study of azacitidine with pembrolizumab in patients with intermediate‐1 or higher‐risk myelodysplastic syndromeBritish Journal of Haematology · 2021
- Outcomes of TP53‐mutant acute myeloid leukemia with decitabine and venetoclaxCancer · 2021
- Acute promyelocytic leukemia current treatment algorithmsSHILAP Revista de lepidopterología · 2021
- Outcomes in patients with newly diagnosed TP53‐mutated acute myeloid leukemia with or without venetoclax‐based therapyCancer · 2021
- Only SF3B1 mutation involving K700E independently predicts overall survival in myelodysplastic syndromesCancer · 2021
- Impact of Philadelphia chromosome‐like alterations on efficacy and safety of blinatumomab in adults with relapsed/refractory acute lymphoblastic leukemia: A post hoc analysis from the phase 3 TOWER studyAmerican Journal of Hematology · 2021
- Open-Label Phase II Prospective, Randomized, Controlled Study of Romyelocel-L Myeloid Progenitor Cells to Reduce Infection During Induction Chemotherapy for Acute Myeloid LeukemiaJournal of Clinical Oncology · 2021
- Hyper‐CVAD plus ofatumumab versus hyper‐CVAD plus rituximab as frontline therapy in adults with Philadelphia chromosome–negative acute lymphoblastic leukemia: A propensity score analysisCancer · 2021
- Core binding factor acute myelogenous leukemia-2021 treatment algorithmBlood Cancer Journal · 2021
- Impact of frontline treatment approach on outcomes of myeloid blast phase CMLJournal of Hematology & Oncology · 2021
- Ibrutinib Plus Venetoclax for First-line Treatment of Chronic Lymphocytic LeukemiaJAMA Oncology · 2021
- Clonal dynamics and clinical implications of postremission clonal hematopoiesis in acute myeloid leukemiaBlood · 2021
- Machine learning integrates genomic signatures for subclassification beyond primary and secondary acute myeloid leukemiaBlood · 2021
- Venetoclax Combined With FLAG-IDA Induction and Consolidation in Newly Diagnosed and Relapsed or Refractory Acute Myeloid LeukemiaJournal of Clinical Oncology · 2021
- Inotuzumab ozogamicin with bosutinib for relapsed or refractory Philadelphia chromosome positive acute lymphoblastic leukemia or lymphoid blast phase of chronic myeloid leukemiaAmerican Journal of Hematology · 2021
- Immunotherapy in Acute Myeloid Leukemia: Where We StandFrontiers in Oncology · 2021
- Leukemia stemness and co-occurring mutations drive resistance to IDH inhibitors in acute myeloid leukemiaNature Communications · 2021
- Long‐term results of low‐intensity chemotherapy with clofarabine or cladribine combined with low‐dose cytarabine alternating with decitabine in older patients with newly diagnosed acute myeloid leukemiaAmerican Journal of Hematology · 2021
- Impact of splicing mutations in acute myeloid leukemia treated with hypomethylating agents combined with venetoclaxBlood Advances · 2021
- A phase I/II study of the combination of quizartinib with azacitidine or low-dose cytarabine for the treatment of patients with acute myeloid leukemia and myelodysplastic syndromeHaematologica · 2021
- Outcome of patients with chronic myeloid leukemia in lymphoid blastic phase and Philadelphia chromosome–positive acute lymphoblastic leukemia treated with hyper‐CVAD and dasatinibCancer · 2021
- De novo acute myeloid leukemia: A population‐based study of outcome in the United States based on the Surveillance, Epidemiology, and End Results (SEER) database, 1980 to 2017Cancer · 2021
- Prognostic factors for progression in patients with Philadelphia chromosome‐positive acute lymphoblastic leukemia in complete molecular response within 3 months of therapy with tyrosine kinase inhibitorsCancer · 2021
- Prognostic value of measurable residual disease after venetoclax and decitabine in acute myeloid leukemiaBlood Advances · 2021
- Duration of cytopenias with concomitant venetoclax and azole antifungals in acute myeloid leukemiaCancer · 2021